Eli Lilly and Company $LLY Stake Raised by Indie Asset Partners LLC

Indie Asset Partners LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 623.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,214 shares of the company’s stock after buying an additional 7,941 shares during the quarter. Eli Lilly and Company comprises 9.4% of Indie Asset Partners LLC’s portfolio, making the stock its biggest holding. Indie Asset Partners LLC’s holdings in Eli Lilly and Company were worth $7,030,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Sumitomo Mitsui Financial Group Inc. bought a new stake in Eli Lilly and Company in the second quarter worth $27,000. Evolution Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $29,000. Steph & Co. increased its holdings in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after buying an additional 29 shares during the last quarter. Financial Gravity Companies Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $31,000. Finally, Bare Financial Services Inc lifted its holdings in shares of Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 29 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on LLY shares. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Friday, December 19th. Zacks Research downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Rothschild & Co Redburn upped their price target on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a report on Monday, January 26th. Finally, Truist Financial set a $1,281.00 price objective on Eli Lilly and Company in a report on Thursday, February 5th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,217.71.

Eli Lilly and Company Trading Up 2.3%

LLY opened at $1,038.59 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock’s fifty day moving average is $1,051.78 and its two-hundred day moving average is $904.70. The company has a market capitalization of $981.86 billion, a P/E ratio of 45.25, a PEG ratio of 1.18 and a beta of 0.39. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 112.50% and a net margin of 31.66%.The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period in the prior year, the business earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 26.14%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion, adding an RNA platform that broadens its pipeline beyond protein therapeutics and supports long‑term growth expectations. Eli Lilly and Company (LLY) to Acquire Orna Therapeutics in $2.4B Deal to Expand RNA Pipeline
• Positive Sentiment: Local approvals move forward for major manufacturing investments (Huntsville ~$6B; European site activity reported), increasing supply capacity for growth drugs and supporting revenue scalability. Huntsville City Council approves Eli Lilly agreement to build $6 billion manufacturing plant
• Positive Sentiment: Analysts are turning more bullish after Lilly’s recent results and outlook — new buy ratings and bullish coverage reinforce investor confidence in near‑term earnings power. Eli Lilly Stock (LLY) Gets New ‘Buy Rating’ After Strong Earnings
• Neutral Sentiment: Lilly has built about $1.5 billion of pre‑launch inventory of its experimental oral weight‑loss pill (orforglipron) ahead of an expected FDA decision in April — a sign of commercial readiness but also a capital outlay that could weigh on short‑term cash if approval is delayed. Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
• Neutral Sentiment: Industry commentary highlights a “big reset” in pharma around pricing, pipelines and patent timing; this frames a mixed backdrop where growth leaders like Lilly face both opportunity and policy/price scrutiny. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Competitive dynamics in the obesity market are evolving (reports of peers altering presentation/packaging strategies), a factor that may affect price, share and margin dynamics but not an immediate earnings shock. Novo to follow Lilly and sell obesity shot Wegovy in vials
• Negative Sentiment: Regulatory binary ahead: the April FDA decision on the oral GLP‑1 candidate represents a material near‑term catalyst — a rejection or delay could trigger downside given the $1.5B inventory and market expectations. Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.